F-18-fluorodeoxyglucose PET Imaging Alters Clinical Decision Making in Patients with Impaired Ventricular Function

Overview

Journal Am J Cardiol

Specialty Cardiology & Vascular Diseases

Date 1997 Apr 15

PMID 9114769

Citations 9

Authors

R S Beanlands

R A deKemp

S Smith

H Johansen

T D Ruddy

Affiliations

Soon will be listed here.

Abstract

The effect of F-18-fluorodeoxyglucose positron emission tomography imaging on decision making in the selection of patients with impaired ventricular function for revascularization was determined in 87 patients. In 57% of patients, positron emission tomography data influenced management decisions, indicating an important effect of myocardial viability determination on difficult therapy decisions in these patients.

Citing Articles

Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.

Ont Health Technol Assess Ser. 2012; 5(16):1-167.

PMID: 23074467 PMC: 3385418.

Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.

Ont Health Technol Assess Ser. 2012; 10(16):1-80.

PMID: 23074393 PMC: 3377573.

Viability assessment with MRI is superior to FDG-PET for viability: Pro.

Maddahi J J Nucl Cardiol. 2010; 17(2):292-7.

PMID: 20225004 DOI: 10.1007/s12350-010-9201-y.

Present and future of clinical cardiovascular PET imaging in Europe--a position statement by the European Council of Nuclear Cardiology (ECNC).

Le Guludec D, Lautamaki R, Knuuti J, Bax J, Bengel F Eur J Nucl Med Mol Imaging. 2008; 35(9):1709-24.

PMID: 18581113 DOI: 10.1007/s00259-008-0859-1.

(13)N-ammonia myocardial perfusion imaging with a PET/CT scanner: impact on clinical decision making and cost-effectiveness.

Siegrist P, Husmann L, Knabenhans M, Gaemperli O, Valenta I, Hoefflinghaus T Eur J Nucl Med Mol Imaging. 2007; 35(5):889-95.

PMID: 18057933 DOI: 10.1007/s00259-007-0647-3.